Market Overview

UPDATE: Jefferies Raises PT to $23 on Solazyme Post Q3 Beat

Related SZYM
Mid-Afternoon Market Update: Inovio Rallies on Vaccine Award; Citigroup Remains Down on Stress Test Results
Mid-Day Market Update: US Stocks Fall; Citigroup Shares Slip After Failed Stress Test Results

Jefferies reiterated its Buy rating on Solazyme (NASDAQ: SZYM) and raised its price target from $22 to $23.

Jefferies commented, "Q3 was $0.06 better than consensus ($0.05 above our forecast). The current projects remain on track, but the real milestones were Bunge expanding its plans even before Moema starts, a new agreement with ADM, another tailored food oil and a test marketing program for Soladiesel. The focus now shifts to winning downstream partnerships."

Solazyme closed at $7.09 on Wednesday.

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Most Popular

Related Articles (SZYM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free